Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Nico Gagelmann"'
Autor:
Nico, Gagelmann, Nicolaus, Kröger
Publikováno v:
International Journal of Hematology. 115:619-625
In this review, we will outline dimensions in which outcome of patients with myelofibrosis undergoing curative treatment can be optimized: patient selection, transplant procedure, and posttransplant prevention or treatment of relapse. For patient sel
Autor:
Nicolaus Kröger, Nico Gagelmann
Publikováno v:
Haematologica
Allogeneic hematopoietic stem-cell transplantation is a potentially curative therapy for various hematologic diseases. An essential component of this procedure is the pre-transplant conditioning regimen, which should facilitate engraftment and reduce
Autor:
Nico Gagelmann, Christine Wolschke, Rachel B. Salit, Thomas Schroeder, Markus Ditschkowski, Victoria Panagiota, Bruno Cassinat, Felicitas Thol, Anita Badbaran, Marie Robin, Hans Christian Reinhardt, Francis Ayuk, Michael Heuser, Bart L. Scott, Nicolaus Kröger
Publikováno v:
Blood advances. 6(4)
Accelerated-phase myelofibrosis, currently defined by circulating blasts 10% to 19%, usually confers very high risk for progression and poor outcome. The outcome of hematopoietic stem cell transplantation for accelerated-phase myelofibrosis has not b
Autor:
Radwan Massoud, Evgeny Klyuchnikov, Nico Gagelmann, Tatiana Zabelina, Christine Wolschke, Francis Ayuk, Ulrike Fritzsche-Friedland, Axel Zander, Nicolaus Kröger
Publikováno v:
Bone marrow transplantation. 57(10)
Data on the influence of different Anti-lymphocyte globulin (ATLG) doses on graft versus host disease (GVHD) incidence and immune reconstitution in matched unrelated (MUD) allogeneic Stem cell transplantation (allo-SCT) is limited. This retrospective
Autor:
Christine Wolschke, Francis Ayuk, Ute-Marie von Pein, Maximilian Gröger, Axel R. Zander, Nicolaus Kröger, Nico Gagelmann, Max Christopeit, Evgeny Klyuchnikov
Publikováno v:
Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 24(7)
The major reason for treatment failure after allografting in multiple myeloma (MM) is relapse. Donor lymphocyte infusions (DLIs) are considered a valuable post-transplant strategy mainly for relapsed patients but using them to prevent relapse in MM h